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SUMMARY · The term ‘subclinical hypothyroidism’ describes the state of slightly elevated serum
TSH and normal serum free T4 and T3 levels, usually without any other clinical findings character-
istic of hypothyroidism. The state is quite common in the elderly, especially in women. Subclinical
hypothyroidism is most commonly an early stage of overt hypothyroidism. Progression to overt hy-
pothyroidism ranges from 5 to 20 percent per year in patients with slightly elevated serum TSH and
high thyroid antibody levels. Patients with subclinical hypothyroidism may have increased levels of
are total and HDL cholesterol, which are less pronounced than in overt disease but predispose these
patients to the development of severe cardiac disease. For this reason, it is necessary to consider
levothyroxine therapy in some of these patients, in order to improve their quality of life and to pre-
vent development of full-blown disease with all its sequels. Because subclinical hypothyroidism is
common in the elderly (4% - 8% of people older than 60), it is necessary to establish a screening
policy based on serum TSH level measurement.
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Introduction
Subclinical hypothyroidism is a state associated with
slightly elevated serum thyrotropin (TSH) concentration
(5 to 25 mU/L) and normal serum free thyroxine (FT4)
and free triiodothyronine (FT3) concentrations1. Some
authors, especially those studying the neuropsychiatric
aspects of hypothyroidism, also include patients who have
basal serum TSH concentration in the upper normal range
and supranormal serum TSH response to thyrotropin-
releasing hormone (TRH)2.
Subclinical hypothyroidism is usually an asymptom-
atic state. However, some of the patients may have clini-
cal symptoms. Each individual has his/her own setpoint
for optimal concentration of free T4. TSH secretion in-
creases when serum free T4 falls below this optimal level.
Although the normal range for serum free T4 is wide (10
to 36 pmol/L), values below the optimal level but still
within the normal range can be low for this particular
individual.This could explain the occurrence of symptoms
in some patients. However, the symptoms are usually
nonspecific and unreliable to confirm the diagnosis3.
These patients may have mild abnormalities of serum li-
poproteins4,5, significantly higher mean total cholesterol
concentrations6,7, and abnormalities of cardiac function8,9.
The recent Rotterdam study has revealed that subclini-
cal hypothyroidism is an independent risk factor for the
development of atherosclerosis and myocardial infarction
in elderly women10.
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Laboratory Testing
Laboratory confirmation of hypothyroidism consists
of measuring serum TSH and FT4 concentrations. Pri-
mary hypothyroidism is characterized by high serum TSH
concentration and low serum FT4 concentration. Patients
with slightly elevated serum TSH concentration and nor-
mal FT4 concentration have subclinical hypothyroidism.
Secondary hypothyroidism is characterized by low serum
FT4 concentration and serum TSH concentration that
does not show proportional elevation. Additional tests
should be performed to differentiate pituitary and hypo-
thalamic disorders.
Primary hypothyroidism accounts for more than 95
percent of cases. Therefore, serum TSH measurement is
an excellent screening test for hypothyroidism in ambu-
latory patients being evaluated for nonspecific symptoms
such as fatigue, depression, or menstrual irregularity11.
Differential Diagnosis
Besides primary hypothyroidism, there are several
conditions that are associated with increased serum TSH
levels: recovery from nonthyroidal disease11-13,TSH-pro-
ducing pituitary adenoma, adrenal insufficiency14, gener-
alized thyroid hormone resistance, and some drugs
(dopamine antagonists, amiodarone, and sodium ipodate
→ oral cholecystogram dye). Elevated serum TSH con-
centration may rarely be due to resistance to TSH caused
by alterations in TSH receptor or failure of the cell to ex-
press the receptor on its surface. All patients with elevated
serum TSH concentrations associated with these condi-
tions are either hyperthyroid or euthyroid.
Once an elevated serum TSH value has been detected,
the test should be repeated and serum FT4 measured, as
it may be due to laboratory error or an episode of silent
thyroiditis with a hypothyroid stage. In these cases, TSH
will probably be normal if measured again several months
later.
Causes of Subclinical Hypothyroidism
The causes of subclinical hypothyroidism are the same
as those of overt hypothyroidism. The most common
cause is chronic autoimmune thyroiditis (Hashimoto’s
disease). The disease is usually associated with increased
titers of antithyroid antibodies such as antithyroid mi-
crosomal antibodies (antithyroid peroxidase) and anti-
thyroglobulin antibodies. In a study conducted in the
USA, 54% of patients with subclinical hypothyroidism
had chronic autoimmune thyroiditis15. In an English
study, 67% of women and 40% of men with subclinical
hypothyroidism had increased antibody titers16. Another
cause of subclinical hypothyroidism is the treatment of
Graves’ disease, mostly after radioiodine ablative therapy,
which accounted for 39% of cases in the Michigan study15.
About half of clinically euthyroid patients who received
radioiodine for Graves’ hyperthyroidism and up to two
thirds of those treated surgically had elevated serum TSH
concentrations17-19. Antithyroid drugs may also cause
subclinical hypothyroidism20. Inadequate replacement
therapy for overt hypothyroidism is another important
cause, especially in the elderly, found in 37 percent of
patients21. It is usually caused by poor patient compliance
or by inappropriate therapy monitoring. In some patients,
inappropriate therapy may be intentional because of the
coexistent heart disease. A less common cause of subclini-
cal hypothyroidism is the use of medications such as
lithium, iodine and amiodarone. Finally, external radio-
therapy of the neck and thyroid surgery for some indica-
tion other than hyperthyroidism are rare causes of sub-
clinical hypothyroidism.
The Prevalence of Subclinical Hypothyroidism
Subclinical hypothyroidism is quite common in the
elderly. Studies from the United Kingdom and United
States report on the rates of 4% to 8% in the elderly16,22,23.
The prevalence is higher in women than in men24, how-
ever, higher prevalence has also been reported. In the
Framigham study (USA), subclinical hypothyroidism was
recorded in about 16% of women over age 60 and 8% of
elderly men25. In women older than 80, the prevalence of
subclinical hypothyroidism is lower (6%)23. Studies from
Japan report on the rates of 5.5% and 3.2% in women and
men over the age of 40, respectively26. In a study from
South Africa, elevated TSH was found in 6.2% of old-
people home residents from Cape Town27.
Subclinical hypothyroidism is more prevalent in areas
of iodine sufficiency. In European studies (Hungary), its
prevalence ranged from 4.2% in iodine deficient areas to
23.9% in those characterized by increased iodine intake,
despite a similar prevalence of patients with high serum
antibody levels in these areas28.
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Clinical Course
Subclinical hypothyroidism is usually an early stage of
overt hypothyroidism. Progression to overt hypothyroid-
ism occurs in patients with both slightly elevated TSH
and high thyroid antibody levels. The rate of progression
ranges from 5% to 20% per year in different studies. In a
study from the United Kingdom, patients were followed
up after 20 years. The women with slightly elevated se-
rum TSH and high thyroid antibody levels developed
overt hypothyroidism with a 4.3% rate of progression per
year29. In a study including elderly patients, the rate of
progression was 20% per year30. Besides autoimmune thy-
roid disease, another important cause of progression to
overt hypothyroidism is radioiodine ablative therapy or
high-dose external radiotherapy31.
The state of slightly elevated TSH may remain un-
changed. It is more likely in patients who have undergone
thyroid surgery for indications other than hyperthyroid-
ism31. The third possibility, in some cases, is returning to
normal TSH level.
Clinical Features
Some patients with subclinical hypothyroidism may
have nonspecific clinical symptoms such as fatigue, dry
skin, and cold intolerance. These symptoms improved
after treatment with levothyroxine32. Some patients may
have goiter. Many studies investigated the effect of slightly
elevated serum TSH level on serum lipid and apoprotein
levels. The reports were different and contradictory. In the
largest study to date, which included 25 862 participants
in total, patients with mild TSH elevation (5-10 mU/L)
had significantly higher mean total cholesterol concentra-
tions than those with euthyroidism6. Other studies re-
ported on increased levels of lipoprotein a4,5. However,
many studies failed to confirm these findings, and the
levels of serum cholesterol and lipoproteins were similar
in patients with slightly elevated TSH and those with
euthyroidism. A recent Rotterdam study has revealed that
subclinical hypothyroidism and thyroid autoimmunity are
associated with an increased risk of atherosclerosis and
myocardial infarction in elderly women10. Patients with
subclinical hypothyroidism may have abnormalities of
cardiac function8,9.
Progression to overt hypothyroidism is usually slow.
The symptoms and signs of hypothyroidism are less pro-
nounced in elderly patients and may be attributed to ag-
ing. Elderly patients generally suffer from some other dis-
eases with similar or at least partially overlapping clinical
symptoms. Results of Lloyd and Goldberg showed that
clinical examination led to definite diagnosis in only 10%
of patients with verified hypothyroidism33.
Treatment
There are no clear attitudes concerning the treatment
of these patients, however, there are recommendations
proposed by many authors and editorials34-36. Many au-
thors currently recommend treatment for most patients
with subclinical hypothyroidism. Individual approach
probably is most important for decision whether or not to
treat (patients with arrhythmias, coronary heart disease,
etc.). However, follow-up of TSH level is required in pa-
tients with slightly elevated serum TSH.
It seems reasonable to treat patients with TSH level
greater than 10 mU/L and high serum thyroid antibody
level. Treatment will prevent progression to overt hy-
pothyroidism. In patients with TSH level between 5 and
10 mU/L, treatment will improve the symptoms such as
fatigue, constipation, or depression32 and prevent the
growth of goiter37. An important therapeutic benefit is
improvement and correction of serum lipid concentra-
tions8 and myocardial contractility32,38. Considering data
from the Rotterdam study10, treatment will prevent de-
velopment of atherosclerosis and myocardial infarction.
Levothyroxine is a basis for the treatment of hypothyroid-
ism. Patients with subclinical hypothyroidism can be con-
trolled with 25 to 50 mg daily. The initial dose usually is
25 mg daily, rising by 25 mg every four to six weeks after
equilibration has been reached. The final dosage is the
lowest dose required to reduce serum TSH within the
normal range without causing any clinical sequels. Age
and lean mass are the main determinants of dosage re-
quirements. Older patients require lower dosage and
therapy should be slowly instituted, because T4 half-life
increases with age.
Screening Policy
Recommendations for thyroid screening are inconsis-
tent and have not been globally accepted. The cost could
be quite high if applied at the large-scale, population level.
Some authors recommend screening in women older than
40 and in geriatric patients39. One group of researchers
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have shown that TSH screening every five years, starting
from age 35, was cost-effective because progression to
overt hypothyroidism was prevented, serum cholesterol
levels were reduced, and the patient quality of life was im-
proved40.
It seems reasonable to determine TSH level in patients
with nonspecific complaints, positive family or personal
history of thyroid disease, presence of thyroid antibodies,
radiotherapy to the head, neck or chest, other autoimmune
diseases, therapy with lithium, amiodarone or iodine, and
in the elderly36.
The American Thyroid Association recommends that
adults be screened for thyroid dysfunction by measure-
ment of serum TSH concentration, beginning at age 35
and every five years thereafter. The indication for screen-
ing is particularly compelling in women, but it may also
be justified in men41.
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Saæetak
SUPKLINI»KA HIPOTIREOZA
T. JukiÊ, Æ. Labar i Z. KusiÊ
Pojam ‘supkliniËka hipotireoza’ opisuje stanje blago povi¹ene razine TSH uz uredne referentne vrijednosti FT4 i FT3 u
serumu, obiËno bez drugih kliniËkih nalaza znakovitih za hipotireozu. Ovo je stanje Ëesto u starijoj æivotnoj dobi, osobito kod
æena. SupkliniËka hipotireoza je najËe¹Êe rani stadij manifestne hipotireoze. Oko 5% do 20% bolesnika s blago povi¹enim TSH
i visokom koncentracijom tiroidnih protutijela prijeðe u hipotireozu kroz godinu dana. Bolesnici sa supkliniËkom hipotireozom
mogu imati povi¹ene vrijednosti ukupnog i HDL kolesterola, koje su manje izraæene nego u manifestnoj hipotireozi, ali
poveÊavaju rizik za nastanak te¹ke bolesti srca. Zbog navedenih Ëinjenica neophodno je neke od ovih bolesnika lijeËiti tiroksinom
radi pobolj¹anja kvalitete æivota i sprjeËavanja razvoja uznapredovale bolesti sa svim moguÊim posljedicama. Zbog visoke
supkliniËke hipotireoze u starijoj æivotnoj dobi (4% · 8% osoba starijih od 60 godina) neophodno je uvesti metodu probiranja
koja se temelji na mjerenju serumske vrijednosti TSH.
KljuËne rijeËi: Hipotiroidizam; Hipotiroidizam, dijagnostika; Funkcionalne pretrage ¹titnjaËe, metode; Probiranje, metode; Hormoni
¹titnjaËe, analiza
